Company profile
Personalis, Inc.
NASDAQ: PSNL · Healthcare · Medical - Diagnostics & Research
#392 of 1,418 Healthcare companies by revenue29th-percentile growth
EA Score
59CFH 54DQ 68GM 51SS 65
v0.1 · 65/100 weight · provisional
↑ filing timeliness, Altman-Z · ↓ Piotroski F, revenue growth (YoY)
Methodology →Revenue TTM
$69.7M
Rev growth YoY (TTM)
-13.3%
Net income (FY)
-$81.3M
Employees
260
as of 2026-08-10
Market cap
$1.5B
as of 2026-08-10
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$69.6M$69.6M2025
Net income-$81.3M-$81.3M2025
Operating income-$88.1M-$88.1M2025
Total assets$334.2M$334.2M2025
Liabilities$73.0M$73.0M2025
Equity$261.2M$261.2M2025
Revenue trend
FY2019 – FY2025 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY25
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Personalis, Inc.’s revenue?
Personalis, Inc. booked $69.6M in FY2025 revenue, contracting 18% year over year — slower than 71% of Healthcare companies we track, at a -116.7% net margin.
Peers · Healthcare
Viridian Therapeutics, Inc.66BCodexis, Inc.61CBlack Diamond Therapeutics, Inc.60CRockwell Medical, Inc.60CVir Biotechnology, Inc.48DIntellia Therapeutics, Inc.57CNeighbors
Alameda →Key facts
CEOChristopher Hall
SectorHealthcare
IndustryMedical - Diagnostics & Research
HeadquartersFremont, CA
ExchangeNASDAQ: PSNL
Employees260
IPO date2019-06-20
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.